Project Grant K99HL173685
Award Date
8/9/24
Completion Date
7/31/26
Dollars Obligated
$150K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $1,102,957 to The Leland Stanford Junior University to conduct a comprehensive research program focused on understanding the relationship between cancer and cardiovascular disease. The key objectives are to: Utilize epidemiological and genetic analysis approaches to map causal associations and overlapping genetic factors between cancer...
This Project Grant award of $117,804 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at The Leland Stanford Junior University (Stanford University) to investigate the role of macrophages and CXCR3+ T-cells in the development of immune checkpoint inhibitor (ICI)-induced myocarditis. The research aims to define the key interactions between macrophages and T-cells that drive inflammation in the heart, with...
This $717,246 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a 4-year research project led by The Leland Stanford Junior University to elucidate the molecular mechanisms underlying cardiovascular toxicity associated with the cancer drug carfilzomib. The key objectives are to: Confirm carfilzomib-induced cardiovascular dysfunction phenotypes in a multiple myeloma mouse model and perform single-cell RNA sequencing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will provide $167,864 to The Leland Stanford Junior University to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity. The key objectives are to: 1) retrospectively examine cardiac and oncologic outcomes associated with ICI cardiotoxicity, 2) retrospectively examine the risks of ICI continuation after...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $433,824 award supports research to understand the metabolic mechanisms underlying diabetic cardiomyopathy, a cardiovascular complication of type 2 diabetes. The research will utilize human induced pluripotent stem cell (iPSC) models to investigate interactions between different...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $2,009,636.00 to The Leland Stanford Junior University (Stanford University) to support research on gene regulatory networks controlling smooth muscle phenotype and vascular disease risk. The key objectives are to map the epigenomic and transcriptomic regulatory elements that mediate the transition of smooth muscle cells...
This $684,794 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund a research project to investigate the role of the blood vascular system and endothelial cells in the regeneration of the thymus after cytotoxic treatments. The research aims to utilize novel intravital imaging techniques to directly analyze changes in the thymus microenvironment, vascular heterogeneity, and tissue oxygenation in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $331,344 to The Leland Stanford Junior University to conduct research on the gene regulatory mechanisms of the coronary artery disease gene PRDM16 and its effects on smooth muscle cell phenotypic modulation. The research aims to determine the regulatory mechanisms by which PRDM16 suppresses smooth muscle cell phenotypic modulation...
This $1,406,736 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research project to understand the mechanisms and impact of coronary artery patterning. The principal investigator at the Palo Alto Veterans Institute for Research (PAVIR) will leverage the Million Veteran Program and large clinical datasets from the VA healthcare system to identify genetic factors influencing coronary artery anomalies, dominance,...
The federal Project Grant award of $165,672 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of cardiac troponin I (cTnI) in inhibiting mitochondrial function and contributing to genetic cardiomyopathies. The research aims to determine the effects of cTnI phosphorylation, truncation, and pathogenic mutations on mitochondrial function, as well as test the therapeutic potential of...